Jefferies starts Cabaletta Bio stock coverage with Buy, sets 36 target By Investing.com - Investing.com
688065 Stock | 42.02 0.48 1.13% |
About 62% of Cathay Biotech's investor base is looking to short. The analysis of overall sentiment of trading Cathay Biotech stock suggests that many investors are alarmed at this time. The current market sentiment, together with Cathay Biotech's historical and current headlines, can help investors time the market. In addition, many technical investors use Cathay Biotech stock news signals to limit their universe of possible portfolio assets.
Cathay |
Jefferies starts Cabaletta Bio stock coverage with Buy, sets 36 target By Investing.com Investing.com
Read at news.google.com
Cathay Biotech Fundamental Analysis
We analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Last Dividend Paid
Last Dividend Paid Comparative Analysis
Cathay Biotech is currently under evaluation in last dividend paid category among its peers. Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
Cathay Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cathay Biotech stock to make a market-neutral strategy. Peer analysis of Cathay Biotech could also be used in its relative valuation, which is a method of valuing Cathay Biotech by comparing valuation metrics with similar companies.
Peers
Cathay Biotech Related Equities
002460 | Jiangxi Ganfeng | 1.84 | ||||
600160 | Zhejiang Juhua | 0.70 | ||||
603260 | Hoshine Silicon | 0.08 | ||||
600010 | Inner Mongolia | 0.51 | ||||
600309 | Wanhua Chemical | 0.77 | ||||
600547 | Shandong Gold | 1.27 | ||||
600019 | Baoshan Iron | 1.60 | ||||
601899 | Zijin Mining | 1.96 | ||||
000807 | Yunnan Aluminium | 2.83 |
Complementary Tools for Cathay Stock analysis
When running Cathay Biotech's price analysis, check to measure Cathay Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cathay Biotech is operating at the current time. Most of Cathay Biotech's value examination focuses on studying past and present price action to predict the probability of Cathay Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cathay Biotech's price. Additionally, you may evaluate how the addition of Cathay Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |